Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04735510
Other study ID # BFS-RGN-01
Secondary ID
Status Withdrawn
Phase Phase 3
First received
Last updated
Start date May 2021
Est. completion date September 2021

Study information

Verified date April 2023
Source Boston Sight
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this prospective observational pilot study is to evaluate the tolerability and safety of RESTASIS (cyclosporine ophthalmic solution 0.05%) when added to the PROSE (Prosthetic Replacement of the Ocular Surface Ecosystem) lens reservoir in patients with ocular surface disease (OSD).


Description:

For this study, all subjects will receive Restasis (Cyclosporine ophthalmic emulsion 0.05%). One drop of the dispensed study drop will be instilled in the PROSE lens reservoir twice a day and the remainder of the reservoir will be filled with normal saline (0.9% sodium chloride solution). In order to standardize solutions used in the PROSE reservoir, all patients recruited will be either currently using or will be switched to buffered preservative-free normal saline (Purilens, Lifestyle Inc., pH 7.4 ) to better match the reported pH of RESTASIS (pH 6.5-8.05).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date September 2021
Est. primary completion date September 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written Informed Consent has been obtained prior to any study-related procedures taking place 2. Subject is Male or Female, 18 years of age or older prior to the initial visit 3. Is an established wearer of PROSE devices for > 6 months in both eyes 4. Has a finalized PROSE lens design in both eyes, in the opinion of the clinician 5. The PROSE design does NOT include fenestrations 6. Subject requires PROSE devices to treat symptoms and/or signs from underlying dry eye disease, GVHD, Sjogren's syndrome, limbal stem cell deficiency, keratoconjunctivitis sicca, or ocular surface disease 7. Baseline Corneal staining grade of 2 or higher in total, both eyes combined (NEI Grading System) 8. Baseline Ocular Surface Disease Index 13 or greater 9. In the opinion of the investigator, the subject can follow study instructions 10. In the opinion of the investigator, the subject can complete all study procedures and visits 11. Able to wear PROSE device continuously for at least 6 hours at a time without removal, in each eye 12. Able to wear PROSE device for at least 10 total hours a day, in each eye 13. Able to wear PROSE device in subsequent continuous sessions of 6 hours, followed by a break to re-instill Restasis in device bowl, followed by another period of continuous wear of at least 4 hours 14. Currently using buffered preservative free normal saline (Purilens) in the device bowl or willing to transition to buffered preservative free normal saline (Purilens) use in the device bowl during the study Exclusion Criteria: 1. Is currently participating in any other type of eye-related clinical or research study 2. Is pregnant or nursing as reported by the subject. 3. Has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound study outcomes, or may significantly interfere with the subject's participation in the study. 4. Has had previous ocular surgery within the past 12 weeks. 5. Currently uses or has a prior history of using Restasis in the last 3 months 6. Currently uses or has a prior history of using Cequa in the last 3 months 7. Is currently using Xiidra and has been using Xiidra for less than 3 months 8. Has a history of an allergic reaction or hypersensitivity to any active or inactive ingredient found in Restasis or Cequa or Purilens. 9. Is wearing a PROSE device with Tangible HydraPEG coating 10. The subject is not wearing their PROSE devices daily 11. The subject is only wearing a device for one eye. 12. The participant is monocular 13. The subject wears a PROSE lens with fenestrations 14. The participant carries a diagnosis of glaucoma or ocular hypertension or glaucoma suspect AND is currently using glaucoma medications 15. The participant is NOT able to wear PROSE devices for 6 hours continuously, followed by a break to re-instill Restasis, followed by an additional period of at least 4 hours of continuous wear 16. Allergy to sodium fluorescein 17. Allergy to lissamine green 18. Allergy or intolerance to Purilens solution. -

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
cyclosporine ophthalmic emulsion 0.05%
All subjects will receive restasis

Locations

Country Name City State
United States BostonSight Needham Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Boston Sight

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Slit lamp exam The PI will perform a slit lamp exam and staining to measure conjunctival redness Baseline
Other Slit lamp exam The PI will perform a slit lamp exam and staining to measure conjunctival redness 1 week
Other Slit lamp exam The PI will perform a slit lamp exam and staining to measure conjunctival redness 1 month
Other Corneal Staining The PI will perform a slit lamp exam and staining to measure corneal staining baseline
Other Corneal Staining The PI will perform a slit lamp exam and staining to measure corneal staining 1 week
Other Corneal staining The PI will perform a slit lamp exam and staining to measure corneal staining 1 month
Primary subjective responses regarding symptoms Subjects will be given a baseline tolerability questionnaire Disease Index (OSDI) Baseline
Primary subjective responses regarding symptoms Subjects will be given a baseline tolerability questionnaire Disease Index (OSDI) 1 week
Primary subjective responses regarding symptoms Subjects will be given a baseline tolerability questionnaire Disease Index (OSDI) 1 month
Secondary Oculus keratograph scan A scan of the eye surface will classify eye redness Baseline
Secondary Oculus keratograph scan A scan of the eye surface will classify eye redness 1 week
Secondary Oculus keratograph scan A scan of the eye surface will classify eye redness 1 month
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04067973 - Impact of Prematurity on the Optic Nerve
Completed NCT04828057 - Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Not yet recruiting NCT06375343 - Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive® Phase 1
Completed NCT00346450 - Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Transplantation Phase 3
Completed NCT04351100 - Efficacy of Diacerein on Ocular Surface Disease in Degenerative Arthritis Patients
Completed NCT03659955 - Autologous Blood Treatment for Ocular Surface Disease N/A
Completed NCT04536129 - Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure N/A
Completed NCT01254370 - Safety and Efficacy Study of Catioprost® (Unpreserved Latanoprost 0.005% Emulsion) Compared to Travatan Z® to Treat Glaucoma and Ocular Surface Disease Phase 2
Completed NCT00554411 - Assessing Ocular Surface Changes After Changing Glaucoma Medications N/A
Completed NCT03769454 - A Phase I Study of PP-001 Eye Drops in Healthy Adult Volunteers Phase 1
Recruiting NCT06256770 - Evaluation of the Safety and Efficacy of Rigid Breathable Scleral Contact Lenses for the Correction of Ametropia
Completed NCT04673604 - From Preserved, to Preservative-free Cyclosporine 0.1% Enhanced Triple Glaucoma Therapy N/A
Not yet recruiting NCT06370585 - Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF Phase 1
Suspended NCT00348114 - Transplantation of Cultivated Limbal Epithelium on Amniotic Membrane for Limbal Stem Cell Deficiency Phase 2
Recruiting NCT04010422 - Ocular Function in Autism Spectrum Disorder
Completed NCT05528016 - Short and Long-term Results of Skin Versus Skin Plus Orbicularis Resection Blepharoplasty N/A
Completed NCT04452279 - Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification N/A
Completed NCT04535388 - LK Scleral Lens for Patients With Intractable Ocular Surface Diseases N/A
Recruiting NCT06298890 - The Pattern of Dry Eye Disease After Cataract Surgery
Completed NCT02802137 - 24-hour Efficacy and Ocular Surface With Talfuprost and Triple Combined Therapy Phase 4